The global network point-of-care glucose testing market size is expected to reach USD 1.79 billion by 2030, registering a CAGR of 4.4% from 2024 to 2030, according to a new report. Increasing demand for safe and accurate remote patient monitoring options and the need for data-based treatment regimens are major factors driving the market. The integration of advanced technologies including Bluetooth Low Energy (BLE) and Infrared is expected to fuel the market growth in the upcoming years.
Expanding patient base in Asia Pacific and the Middle East and the high demand for advanced diabetes management systems are creating significant growth opportunities in these regions. These regions also include some of the highly preferred destinations for medical tourism. Increasing demand for world-class healthcare services and rising adoption of advanced technology are some of the factors boosting the market growth in these regions.
Network point-of-care glucose meters were extensively used in COVID-19 care. This enabled doctors to remotely observe glucose levels with minimal risk of infection. In addition, a large amount of data is still being used to customize treatment plans for diabetic COVID-19 patients. Preference for telemedicine and trends of home healthcare settings for chronic patients are some of the factors expected to expand the applications of network-based point-of-care devices.
This product will be delivered within 2 business days.
Expanding patient base in Asia Pacific and the Middle East and the high demand for advanced diabetes management systems are creating significant growth opportunities in these regions. These regions also include some of the highly preferred destinations for medical tourism. Increasing demand for world-class healthcare services and rising adoption of advanced technology are some of the factors boosting the market growth in these regions.
Network point-of-care glucose meters were extensively used in COVID-19 care. This enabled doctors to remotely observe glucose levels with minimal risk of infection. In addition, a large amount of data is still being used to customize treatment plans for diabetic COVID-19 patients. Preference for telemedicine and trends of home healthcare settings for chronic patients are some of the factors expected to expand the applications of network-based point-of-care devices.
Network Point-of-Care Glucose Testing Market Report Highlights
- Network point-of-care devices were in high demand during the first and second wave of COVID-19 owing to their advantage of remote patient monitoring
- Based on product, the Accu-Chek Inform II segment dominated the market and accounted for a revenue share of 48.4% in 2023 and is expected to expand at a lucrative growth rate during the forecast period
- North America dominated the market with a revenue share of 40.7% in 2023 and is predicted to maintain its lead over the forecast period owing to the factors such as the presence of major players and high adoption rate
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Network Point-of-Care Glucose Testing Market Variables, Trends, & Scope
Chapter 4. Network Point-of-Care Glucose Testing Market: Product Estimates & Trend Analysis
Chapter 5. Network Point-of-Care Glucose Testing Market: Regional Estimates & Trend Analysis
Chapter 6. Competitive Landscape
Companies Mentioned
- Abbott, LLC
- Nova Biomedical
- Danaher
- F. Hoffmann-La Roche Ltd.
- Ascensia Diabetes Care Holdings AG.
- Prodigy Diabetes Care, LLC
- Nipro Corporation Japan
- ACON Laboratories, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 90 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1.33 Billion |
| Forecasted Market Value ( USD | $ 1.79 Billion |
| Compound Annual Growth Rate | 4.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
